On the efficacy of parenteral chondroitin sulfate in patients with osteoarthritis in the presence of grade 1 functional joint failure
- 作者: Sarvilina I.1
-
隶属关系:
- OOO «Novomeditsina» (New Medicine) Medical Center
- 期: 卷 33, 编号 1 (2022)
- 页面: 31-40
- 栏目: Articles
- URL: https://journals.rcsi.science/0236-3054/article/view/142827
- DOI: https://doi.org/10.29296/25877305-2022-01-05
- ID: 142827
如何引用文章
详细
It is necessary to reconsider the use of drugs affecting the pathobiochemical pathways in the development of cartilaginous tissue structural changes in functional joint failure (FJF) in the presence of osteoarthritis (OA). Objective. To evaluate the efficacy of the parenteral formulation of the pharmaceutically active substance chondroitin sulfate (CS; Chondroguard®, CS-Bioactive© Bioiberica S.A.U., Spain, manufactured by the ZAO «FarmFirma “Sotex», Russia) in patients with Stage II knee OA (KOA) and grade 1 FJF. Subjects and methods. A 50-day open-label, prospective, controlled, randomized trial was conducted according to inclusion/exclusion criteria. The trial enrolled 82 patients with Stage II KOA, grade 1 FJF, who were divided into two groups: 1) 42 patients received CS (Chondroguard®, 100 mg/ml) intramuscularly every other day; the first three 1-ml injections; and if well tolerated, the fourth and next 2-ml injections (a 50-day treatment cycle included 25 injections); 2) 40 patients took celecoxib at a dose of 200 mg/day, which can be reduced to 100 mg/day and discontinued. On days 0 and 50, the investigators assessed pain intensity using a visual analogue scale (VAS), Lequesne’s functional indices, WOMAC, and joint ultrasound data and the safety of therapy using the WHO and Naranjo scales. The data were statistically processed applying the Statistica 10.0 software (StatSoft, Inc., USA). Results. Chondroguard® therapy was well tolerated by patients and was accompanied by a significant improvement in pain intensity scores according to VAS (U test=7.79; p<0.0001), a decrease in the severity of OA according to Lequesne’s indices (U test=7.79; p=< 0.0001), and WOMAC (U test=7.12; p=<0.0001). There was a decline in the number of combined signs of synovitis and tendonitis in Group 1 (Chondroguard®) as compared with that in Group 2 (celecoxib). A marked improvement in the Lequesne subscales («Pain and discomfort», «Walking distance», «Daily activity») and WOMAC was also recorded in patients receiving Chondroguard®. Conclusion. The use of Chondroguard® is effective and safe in patients with Stage II KOA and grade 1 FJF, who require outpatient care.
作者简介
I. Sarvilina
OOO «Novomeditsina» (New Medicine) Medical Center
编辑信件的主要联系方式.
Email: isarvilina@mail.ru
MD
俄罗斯联邦, Rostov-on-Don参考
- Насонова В.А., Фоломеева О.М. Медико-социальное значение XIII класса болезней для населения России. Научно-практическая ревматология. 2001; 1: 7-11
- Lawrence R.C., Felson D.T., Helmick C.G. et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.I. Arthritis Rheum. 2008; 58 (1): 26-35. DOI: 10.1002/ art.23176
- Murphy L., Schwartz T.A., Helmick C.G. et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008; 59 (9): 1207-13. DOI: 10.1002/ art.24021
- Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2020; 448 с.
- Балабанова Р.М., Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения России за 2000-2010 гг. Научно-практическая ревматология. 2012; 50 (3): 10-2 doi: 10.14412/1995-4484-2012-702
- Litwic A., Edwards M.H., Dennison E.M. et al. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013; 105 (1): 185-99. doi: 10.1093/bmb/lds038
- Leyland K.M., Gates L.S., Sanchez Santos M.T. et al. The PCCOA Steering Committee. Knee osteoarthritis and time to all cause mortality in six community based cohorts: an international meta analysis of individual participant level data. Aging Clin Exp Res. 2021; 33: 529-45. doi: 10.1007/s40520-020-01762-2
- Pal C.P., Singh P., Chaturvedi S. et al. Epidemiology of knee osteoarthritis in India and related factors. Indian J. Orthop. 2016; 50 (5): 518-22. doi: 10.4103/00195413.189608
- Эрдес Ш.Ф., Фоломеева О.М. Инвалидность взрослого населения России, обусловленная ревматическими заболеваниями. РМЖ. 2007; 15 (26): 1946-50
- Cross M., Smith E., Hoy D. et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73 (7): 1323-30. doi: 10.1136/annrheumdis-2013-204763
- Samuels J., Krasnokutsky S., Abramson S.B. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008; 66: 244-50.
- Samuel A., Kanimozhi D. Outcome measures used in patient with knee osteoarthritis: With special importance on functional outcome measures. Int J. Health Sci. 2019; 13 (1): 52-60.
- Клиническая фармакология. Национальное руководство. Под ред. Белоусова Ю.Б., Лепахина В.К., Кукеса В.Г., Петрова В.И. М.: ГЭОТАР-Медиа, 2009
- Алексеева Л.И. Препараты замедленного действия в лечении ОА. РМЖ. 2012; 7: 389-93
- Reginster J.-Y., Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021; 33 (1): 37-47. doi: 10.1007/s40520-020-01643-8
- Волошин В.П., Еремин А.В., Санкаранараянан С.А. и др. Исследование эффективности действия препарата Хондрогард (хондроитина сульфат) у пациентов с остеоартрозом. Трудный пациент. 2015; 13 (3): 2932
- Лила А.М., Громова О.А., Торшин И.Ю. и др. Молекулярные эффекты Хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 88-97 doi: 10.14412/2074-27112017-3-88-97
- Гонартроз. Клинические рекомендации [Gonartroz. Klinicheskie rekomendatsii (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/667_1
- Коксартроз. Клинические рекомендации [Koksartroz. Klinicheskie rekomendatsii (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/666_1
- Singh J.A., Noorbaloochi S., MacDonald R. et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 1: CD005614. doi: 10.1002/14651 858.cd005 614.pub2
- Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартрита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная Фармакоэкономика и Фармакоэпидемиология. 2020; 13 (4): 399-410 doi: 10.17749/2070-4909/farmakoekonomika.2020.066
- Лила А.М., Ткачева О.Н., Наумов А.В. и др. Место и роль парентеральной формы хондроитина сульфата в терапии остеоартрита: мультидисци-плинарный Консенсус. РМЖ. 2021; 6: 68-74
- Kellgren J.H., Lawrence J.S. Radiographic assessment of osteoarthritis. Ann Rheum Dis. 1957; 16 (4): 494-502. doi: 10.1136/ard.16.4.494
- Смирнов А.В. Атлас рентгенологической диагностики первичного остеоартроза. М.: ИМА-ПРЕСС, 2010
- Zhang W., Doherty M., Peat G. et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69 (3): 483-9. doi: 10.1136/ard.2009.113100